Views & Analysis | Perspectives on pharma industry issues

Sales & Marketing

Wooden pawns representing number of employees

Headcount is not a growth strategy

Deciding when, where, and how quickly to add headcount is rarely straightforward.

Market Access

pharmaphorum podcast Episode 275, Giancarlo Benelli, BeOne Medicines

Europe for life sciences and for patients, with BeOne Medici...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Giancarlo Benelli, SVP & Head of Europe at BeOne Medicines.

R&D

Woman in black suit extends hand of welcome to the company

Changing Faces: Pharma and biotech hires, August 2026

August brought another wave of leadership changes across biotech, pharma, and research organisations.

R&D

Female scientists compares test tubes results

Trial complexity is the new normal

When operationalised effectively, RBQM can support earlier risk detection and more targeted quality improvement.

Sales & Marketing

Pharma's engagement problem: Are we expecting too much from ...

The question is no longer simply how to attract healthcare professionals to an event. The bigger challenge is how to create meaningful engagement.

Views & Analysis

2021 market access prospects for Spain

2021 will be the year when big market access changes – including the far wider use of health economic evaluation – are implemented in Spain.

Views & Analysis

2021 market access prospects for Germany

The market access landscape in Germany is particularly interesting in 2021, as a key component – AMNOG – is ten years old, and that milestone prompts reflections on what has worked well and

Views & Analysis

Common but not normal: It’s time to talk about maternal ment...

As part of our Patients Insights series, the founder and CEO of Motherhood Understood shares her experi

Sales & Marketing

Headcount is not a growth strategy

Deciding when, where, and how quickly to add headcount is rarely straightforward.

Sales & Marketing

Pharma's engagement problem: Are we expecting too much from ...

The question is no longer simply how to attract healthcare professionals to an event. The bigger challenge is how to create meaningful engagement.

Digital

AI in clinical rials and drug development

AI in clinical trials: Building better trials before they st...

With AI, trial sponsors are now reducing risk, accelerating timelines, and driving innovation by modelling what is most likely to work in the future.

Digital

pharmaphorum podcast Episode 274, Erik Janssen, UCB

Ethical AI & trust-driven innovation: UCB’s Erik Janssen

How can pharma lead the way in ethical AI and trust-driven innovation?

Market Access

Europe for life sciences and for patients, with BeOne Medici...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Giancarlo Benelli, SVP & Head of Europe at BeOne Medicines.

Market Access

Blue and white pills in pharma manufacturing line

Pharma’s most expensive question is the last one asked

Whether a drug can secure reimbursement is pharma's billion-dollar question, and the companies that succeed will be those that answer it sooner.

Oncology

How today’s biotechs are helping us Stand Up To Cancer

In recognition of Stand Up To Cancer Day, a look at next-generation treatments that are on the verge of making it into clinical practice.

Oncology

Bridging the innovation gap: Scalable cell therapies, adapti...

Biotech must build manufacturing and trial models that make cell therapies scalable, accessible & commercially viable.

Oncology

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Patients

Woman in yellow jacket blows nose due to hayfever

Redefining the self-care pathway in the evolving hayfever la...

When it comes to hayfever, proactive approach improves patient health literacy and empowers individuals to put their health back in their own hands.

Patients

Pharmacist hands woman prescription medicine with an explanation

Specialty medication access hinges on a 48-hour window

The vast majority of healthcare providers (HCPs) say that PA-related delays directly harm patient outcomes.

Patients

Man lies on floor next to spilled pill bottle, reference to overdose

Decline in overdose deaths ≠ The end of the opioid crisis

Since 2001, International Overdose Day has been observed as a moment to remember those lost to overdose and renew society’s commitment to

Headcount is not a growth strategy

Europe for life sciences and for patients, with BeOne Medici...

Changing Faces: Pharma and biotech hires, August 2026

Trial complexity is the new normal

Pharma's engagement problem: Are we expecting too much from ...

2021 market access prospects for Spain

2021 market access prospects for Germany

Common but not normal: It’s time to talk about maternal ment...

Headcount is not a growth strategy

Pharma's engagement problem: Are we expecting too much from ...

AI in clinical trials: Building better trials before they st...

Ethical AI & trust-driven innovation: UCB’s Erik Janssen

Europe for life sciences and for patients, with BeOne Medici...

Pharma’s most expensive question is the last one asked

How today’s biotechs are helping us Stand Up To Cancer

Bridging the innovation gap: Scalable cell therapies, adapti...

Building a Phase I oncology centre

Redefining the self-care pathway in the evolving hayfever la...

Specialty medication access hinges on a 48-hour window

Decline in overdose deaths ≠ The end of the opioid crisis

Changing Faces: Pharma and biotech hires, August 2026

Trial complexity is the new normal

Mosquitoes, malaria, and UK R&D viral disease vaccine invest...

Electra sets terms for IPO, hoping to raise up to $347m

Discover a new era of healthcare panel engagement: Grounded ...

Sales & Marketing

Digital

Market Access

Editor's Picks

Oncology

Patients

R&D

Editor's Picks